Kisspeptin-10 Research Overview

Discovery and Biological Context

The kisspeptin system was characterised between 2001 and 2003 through two independent discoveries: the identification of GPR54 (now called KISS1R) as an orphan receptor whose activation triggered puberty onset in mice, and the subsequent identification of kisspeptin — encoded by the KISS1 gene — as the endogenous GPR54 ligand. The extraordinary revelation was that this previously obscure neuropeptide system constitutes the primary driver of GnRH pulsatility in the hypothalamus — the fundamental oscillatory output that controls the entire reproductive endocrine axis in all mammals studied.

Kisspeptin is processed from a 145-amino acid precursor into several C-terminal fragments of varying length: Kisspeptin-54 (the predominant circulating form), Kisspeptin-14, Kisspeptin-13, and Kisspeptin-10 — the shortest fragment retaining full GPR54 agonist activity. All active kisspeptin isoforms share the same C-terminal decapeptide (the KP-10 sequence: Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂), which is both necessary and sufficient for GPR54 activation. This makes KP-10 the most tractable research form: shortest, most synthetically accessible, and most potent on a molar basis.

• Sequence (KP-10): Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH₂
• Molecular Weight: 1,302.5 Da
• Receptor: GPR54 / KISS1R (Gq/11-coupled GPCR)
• Gene: KISS1 (chromosome 1q32)
• Primary Brain Expression: Arcuate nucleus; anteroventral periventricular nucleus
• Key Downstream Hormones: GnRH → LH + FSH → Testosterone / Estradiol

The Kisspeptin-GnRH Axis: Master Regulator of Reproduction

HPG Axis — Kisspeptin-Driven Signalling Cascade KNDy Neurons (ARC) → Kisspeptin → GPR54 → GnRH Pulse → LH + FSH Surge → Testosterone / Estradiol

Kisspeptin neurons — particularly those in the arcuate nucleus (ARC) co-expressing neurokinin B (NKB) and dynorphin (forming the KNDy neuron population) — act as the intrinsic pulse generator for GnRH release. NKB provides the self-amplifying excitatory drive within the KNDy network, dynorphin provides the inhibitory reset, and kisspeptin is the output signal that drives GnRH neurons to fire. This KNDy oscillator generates the approximately 90-minute GnRH pulse interval seen in adult men and the variable interval in women across the menstrual cycle.

Exogenous kisspeptin administration — whether as KP-10, KP-54, or synthetic analogues — bypasses the endogenous KNDy oscillator and directly activates GnRH neurons via their GPR54 receptors. The result is a powerful, reliable GnRH pulse followed by measurable LH and FSH surges within 30–90 minutes. This makes kisspeptin one of the most direct available tools for experimentally activating the reproductive endocrine axis at a defined, measurable point in the signalling cascade.

GPR54 Receptor Signalling Mechanism

GPR54 is a Gq/11-coupled G-protein coupled receptor. Kisspeptin binding activates phospholipase C (PLC), generating IP₃ and DAG — leading to intracellular calcium release and PKC activation. This signalling cascade in GnRH neurons triggers action potential firing and GnRH vesicle exocytosis. The calcium signal also activates downstream kinases including ERK1/2, which may contribute to transcriptional changes in GnRH neuron gene expression beyond immediate GnRH release.

Chronic or continuous GPR54 stimulation produces receptor desensitisation and GnRH pulse suppression — a clinically important pharmacological property exploited by continuous kisspeptin analogue infusion in research models and by pharmaceutical GPR54 antagonists under development for endometriosis and prostate cancer (conditions where GnRH suppression is therapeutic). This desensitisation profile means that pulsatile, not continuous, kisspeptin administration is required to maintain or stimulate reproductive axis activity.

LH and Testosterone Research

The most direct evidence for kisspeptin's reproductive axis activation in humans comes from controlled intravenous and subcutaneous infusion studies. In healthy men, a single subcutaneous injection of KP-10 (at doses from 0.3 to 10 nmol/kg) produces a dose-dependent LH surge peaking at 30–60 minutes and a subsequent testosterone rise peaking at 60–120 minutes. The testosterone response is modest in eugonadal men (where the Leydig cell response is constrained by existing sex steroid feedback) but more pronounced in men with hypogonadotropic hypogonadism — where the Leydig cells remain responsive but lack adequate gonadotropin stimulation.

• Kisspeptin Isoform: Kisspeptin-54 (KP-54) — Length: 54 aa — GPR54 Potency: High — Plasma Half-life: ~28 minutes — Primary Research Use: Longer-duration infusion; clinical reproductive studies
• Kisspeptin Isoform: Kisspeptin-14 (KP-14) — Length: 14 aa — GPR54 Potency: High — Plasma Half-life: ~4 minutes — Primary Research Use: Intermediate; less commonly used
• Kisspeptin Isoform: Kisspeptin-10 (KP-10) — Length: 10 aa — GPR54 Potency: Highest (molar) — Plasma Half-life: ~3 minutes — Primary Research Use: Acute GnRH pulse studies; mechanistic research
• Kisspeptin Isoform: Synthetic analogues (e.g. MVT-602) — Length: Variable — GPR54 Potency: Very high (modified) — Plasma Half-life: Hours (modified) — Primary Research Use: Extended-action pharmaceutical development

Hypogonadotropic Hypogonadism Research

Hypogonadotropic hypogonadism (HH) — characterised by low testosterone with inappropriately low or normal LH/FSH — results from deficient GnRH pulsatility and represents a condition where kisspeptin's mechanism is directly relevant. In men with congenital HH (Kallmann syndrome and idiopathic HH), subcutaneous kisspeptin administration robustly activates LH pulsatility and restores testosterone to eugonadal ranges in a substantial proportion of subjects, confirming that their GnRH neurons and pituitary gonadotrophs remain responsive to kisspeptin — the deficit is upstream at the KNDy neuron or Kiss1 signalling level.

Chronic pulsatile kisspeptin infusion (mimicking the physiological KNDy oscillator) has been demonstrated to restore near-normal reproductive function — including spermatogenesis — in men with HH over weeks of treatment. These findings position kisspeptin as a physiologically authentic alternative to conventional pulsatile GnRH therapy (historically administered via programmable infusion pumps) for the research and potential treatment of HH.

Female Reproductive Research

Kisspeptin's role is equally critical in female reproductive endocrinology. The pre-ovulatory LH surge — required for ovulation — is now understood to be triggered by a massive kisspeptin output from anteroventral periventricular (AVPV) nucleus neurons in response to rising estradiol levels (positive feedback). Research in women has demonstrated that exogenous KP-54 infusion can reliably trigger an LH surge and ovulation in women undergoing controlled ovarian stimulation, an application being explored as an alternative to conventional hCG triggers in IVF protocols with potentially lower ovarian hyperstimulation syndrome (OHSS) risk.

Research Significance for HPG Axis Studies > > Kisspeptin-10 is the most powerful available tool for experimentally activating the GnRH pulse generator at a physiologically defined entry point. Unlike hCG or recombinant LH (which bypass the hypothalamus entirely) or GnRH itself (which bypasses kisspeptin), KP-10 activates the axis at the GnRH neuron level — the earliest pharmacologically accessible point in the reproductive cascade. This makes it uniquely informative for research dissecting hypothalamic from pituitary and gonadal components of reproductive axis dysfunction.

Research Use Only. Research Use Only — Disclaimer This document is prepared for laboratory and research reference purposes only. Kisspeptin-10 is not approved by the FDA for any therapeutic indication. All clinical data referenced pertains to investigational use in controlled research settings. This content does not constitute medical advice, diagnosis, or treatment recommendation. Researchers must comply with all applicable institutional and jurisdictional regulations.

References

1. Seminara SB, et al. "The GPR54 gene as a regulator of puberty." *N Engl J Med*. 2003;349(17):1614–1627.

1. Dhillo WS, et al. "Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males." *J Clin Endocrinol Metab*. 2005;90(12):6609–6615.

1. Chan YM, et al. "Kisspeptin resets the hypothalamic GnRH clock in men." *J Clin Endocrinol Metab*. 2011;96(6):E908–E915.

1. Jayasena CN, et al. "Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotrophin secretion in women with hypothalamic amenorrhoea, but chronic administration causes tachyphylaxis." *J Clin Endocrinol Metab*. 2009;94(11):4315–4323.

1. Pinilla L, et al. "Kisspeptins and reproduction: physiological roles and regulatory mechanisms." *Physiol Rev*. 2012;92(3):1235–1316.

1. Skorupskaite K, et al. "The kisspeptin-GnRH pathway in human reproductive health and disease." *Hum Reprod Update*. 2014;20(4):485–500.